New findings in localized and advanced prostate cancer: AUA 2011 review

Canadian Journal of Urology

Volumn 18, Issue 3, 2011, Pages 5683-5688

  Kazzazi, Amir ^a   Momtahen, Shabnam ^a   Bruhn, Aron ^a   Hemani, Micah ^a   Ramaswamy, Krishna ^a   Djavan, Bob ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Markers; Prostate cancer; Prostate specific antigen; Staging

Indexed keywords

TUMOR MARKER;

CANCER STAGING; DISEASE COURSE; GENETIC SCREENING; HUMAN; MALE; OBESITY; PATHOLOGY; PROSTATE TUMOR; REVIEW;

DISEASE PROGRESSION; GENETIC TESTING; HUMANS; MALE; NEOPLASM STAGING; OBESITY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80055090638     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. McCracken S, Housley S, Dominguez-Escrig J et al. The superiority of transperineal template mapping biopsy of the prostate gland over the transrectal saturation approach. [Abstract 188] J Urol Suppl 2011;185(4S):e78.
2. Smith KM, O'Shaughnessy MJ, Rachel M et al. Clinical yield of initial staging workup for high grade prostate cancer. [Abstract 191] J Urol Suppl 2011;185(4S):e79.
3. Gershman B, Wu CL, McDougal WS. The effect of age and prostate size on gleason score upgrading. [Abstract 193] J Urol Suppl 2011; 185(4S):e80.
4. Dinizo M, Chalfin H, Trock B et al. Implications of surgical margin status on prostate cancer-specific survival. [Abstract 192] J Urol Suppl 2011;185(4S):e79-e80.
5. Numao N, Kawakami S, Saito K et al. Negative result in unilateral 13-core biopsy can predict the absence of significant cancer on the ipsilateral lobe with a high accuracy. Implications for hemiablative focal therapy. [Abstract 195] J Urol Suppl 2011; 185(4S):e81.
6. Bivalacqua T, Pierorazio P, Ross A et al. Anatomical Extent of lymph node dissection: impact on men with positive lymph nodes at time of radical prostatectomy. [Abstract 189] J Urol Suppl 2011;185(4S):e117-e118.
7. Helfand BT, McGuire BB, Delli-Zotti KA et al. Frequencies of prostate cancer risk variants in early onset and familial prostate cancer. [Abstract 2286]. J Urol Suppl 2011;185(4S):e916-e917.
8. Ho TS, Aronson WJ, Terris MK et al. Obese men are more likely to have higher PSA nadir values after radical prostatectomy (RP), though this does not explain the higher biochemical recurrence (BCR) rates: results from the search database. [Abstract 2294]. J Urol Suppl 2011;185(4S):e920.
9. Miyake H, Muramaki M, Kamidon S et al. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. [Abstract 2296]. J Urol Suppl 2011;185(4S):e921.
10. Segawa T, Matsumoto K, Sumiyosh T et al. Urine prostate specific antigen test for the detection of local recurrence after radical prostatectomy for prostate cancer. [Abstract 2328]. J Urol Suppl 2011;185(4S):e933-e934.
11. Cary K, Cheng L, Koch M. Change in PSA doubling time after biochemical recurrence in 345 patients following radical prostatectomy. [Abstract 2329]. J Urol Suppl 2011;185(4S):e934.
12. Narita S, Tsuchiya N, Maita S et al. Preoperative serum levels of interlukin-6 and interleukin-12 predict biochemical recurrence in patients with prostate cancer treated using radical prostatectomy. [Abstract 2337]. J Urol Suppl 2011;185(4S):e937.